BUZZ - Wanda Pharmaceutical shares fall as anti-anxiety drug project stalls due to clinical trial failure

October 15 - ** Vanda Pharmaceuticals (VNDA.O) shares fell 1.7% to $4.15 in premarket trading

** The company said late Wednesday that its experimental anti-anxiety drug VQW-765 failed to meet the primary endpoint in a late-stage clinical trial (link)

** In a public speaking stress test, the drug did not reduce stress levels compared to a placebo

** Vanda will pause development plans for VQW-765 while reviewing the full study data

** Oppenheimer analysts said the failed trial "adds pressure on the rest of the company’s pipeline," adding that investors may now set a "higher bar" for Vanda’s other programs

** As of the previous trading day's close, the stock was down 52% year to date

(To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may be inaccurate or lack required context, Reuters does not guarantee the accuracy of the translated text, which is provided for convenience only. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)